Pα+ Psychedelic Bulletin #150: Drug Development and Research Updates
- GH Research’s Lead 5-MeO-DMT Candidate Faces Development Hiccup, Potential Hold-Up
- Deals, Raises and Funding
- Psychae Therapeutics Scores AUD $4.5m to Develop DMT-Based Candidate
- Cybin Closes $30m Offering
- Brain & Behavior Research Foundation Awards Grants to 8 ‘Young Investigators’ Exploring Psychedelics
- Other Rounds
- Psychedelic Drug Development & Research News
- atai Buys Out Remainder of DemeRx’s Ibogaine Asset; Announces Novel 5-HT2A Agonist Candidates
- Compass Commences UK Portion of Phase 3 Trial, Officially Opens Centre for Mental Health Research and Innovation in London
- Awakn Plans to Commence Enrollment for Phase 3 Study of Ketamine for Severe Alcohol Use Disorder in Q1 2024
- Clippings
- Other Psychedelic Business News
- A Nue Lease of Life? Beckley Waves Acquires Struggling At-Home Ketamine Provider Nue Life Health
- 14% of travellers are interested in a psychedelic retreat in 2024
- Clippings
- In the Public Eye
This Issue of the Bulletin primarily focuses on psychedelic drug development and business stories, with around 4,000 words of coverage and analysis.
Elsewhere, we spoke to Booking.com to better understand a headline figure from its travel predictions study, which claims that 14% of travellers are interested in a psychedelic retreat in 2024. We also share clippings and commentary on psychedelics-related news stories from around the world, as well as biotech more broadly.
Companies, organisations and drug candidates mentioned in this Bulletin include: GH Research, GH001, Psychae Therapeutics, Tin Alley Ventures, Reconnect Labs, Filament Health, Psychae Institute, Cybin, Tryp Therapeutics, PharmaDrug, atai Life Sciences, DemeRx, DMX-1002, EntheogeniX, EGX-A, EGX-B, Cyclica, EMP-01, VLS-01, Compass Pathways, COMP369, NHS, Awakn Life Sciences, AWKN-P001, Sunstone Therapies, Kanna Health, Relmada Therapeutics, Nue Life, Beckley Waves, Enthea...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks